BlackRock
UTMD icon

BlackRock’s Utah Medical Products UTMD Stock Holding History

BlackRock’s Portfolio UTMD Stock Details UTMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$11.6M Buy
187,649
+3,112
+2% +$196K ﹤0.01% 3396
2025
Q4 		$10.3M Buy
184,537
+4,715
+3% +$273K ﹤0.01% 3452
2025
Q3 		$11.3M Buy
179,822
+313
+0.2% +$18.5K ﹤0.01% 3393
2025
Q2 		$10.2M Buy
179,509
+18,862
+12% +$1.03M ﹤0.01% 3407
2025
Q1 		$9M Sell
160,647
-7,967
-5% -$477K ﹤0.01% 3362
2024
Q4 		$10.4M Sell
168,614
-11,481
-6% -$742K ﹤0.01% 3407
2024
Q3 		$12.1M Sell
180,095
-16,788
-9% -$1.14M ﹤0.01% 3313
2024
Q2 		$13.2M Sell
196,883
-17,514
-8% -$1.19M ﹤0.01% 3225
2024
Q1 		$15.2M Buy
214,397
+9,976
+5% +$748K ﹤0.01% 3134
2023
Q4 		$17.2M Buy
204,421
+7,004
+4% +$581K ﹤0.01% 3089
2023
Q3 		$17M Buy
197,417
+807
+0.4% +$74.5K ﹤0.01% 3035
2023
Q2 		$18.3M Sell
196,610
-2,427
-1% -$229K ﹤0.01% 3091
2023
Q1 		$18.9M Sell
199,037
-6,477
-3% -$595K ﹤0.01% 3006
2022
Q4 		$20.7M Buy
205,514
+6,911
+3% +$631K ﹤0.01% 3027
2022
Q3 		$16.9M Sell
198,603
-3,319
-2% -$293K ﹤0.01% 3123
2022
Q2 		$17.3M Sell
201,922
-11,222
-5% -$957K ﹤0.01% 3157
2022
Q1 		$19.2M Sell
213,144
-3,863
-2% -$355K ﹤0.01% 3196
2021
Q4 		$21.7M Buy
217,007
+748
+0.3% +$76.3K ﹤0.01% 3220
2021
Q3 		$20.1M Sell
216,259
-8,586
-4% -$758K ﹤0.01% 3272
2021
Q2 		$19.1M Sell
224,845
-4,147
-2% -$359K ﹤0.01% 3333
2021
Q1 		$19.8M Buy
228,992
+6,303
+3% +$554K ﹤0.01% 3188
2020
Q4 		$18.8M Buy
222,689
+7,345
+3% +$626K ﹤0.01% 3037
2020
Q3 		$17.2M Sell
215,344
-5,867
-3% -$487K ﹤0.01% 2944
2020
Q2 		$19.6M Sell
221,211
-2,900
-1% -$260K ﹤0.01% 2810
2020
Q1 		$21.1M Sell
224,111
-1,178
-0.5% -$109K ﹤0.01% 2577
2019
Q4 		$24.3M Buy
225,289
+1,752
+0.8% +$178K ﹤0.01% 2775
2019
Q3 		$21.4M Buy
223,537
+8,433
+4% +$784K ﹤0.01% 2776
2019
Q2 		$20.6M Buy
215,104
+37,509
+21% +$3.16M ﹤0.01% 2830
2019
Q1 		$15.7M Sell
177,595
-11,633
-6% -$1.02M ﹤0.01% 2871
2018
Q4 		$15.7M Buy
189,228
+8,765
+5% +$772K ﹤0.01% 2853
2018
Q3 		$17M Buy
180,463
+1,681
+0.9% +$161K ﹤0.01% 2955
2018
Q2 		$19.7M Buy
178,782
+16,899
+10% +$1.76M ﹤0.01% 2863
2018
Q1 		$16M Buy
161,883
+108
+0.1% +$9.64K ﹤0.01% 2883
2017
Q4 		$13.2M Buy
161,775
+3,164
+2% +$247K ﹤0.01% 3007
2017
Q3 		$11.7M Sell
158,611
-98
-0.1% -$7.05K ﹤0.01% 3080
2017
Q2 		$11.5M Sell
158,709
-1,415
-0.9% -$93.1K ﹤0.01% 3089
2017
Q1 		$9.97M Buy
160,124
+159,876
+64,466% +$10.1M ﹤0.01% 3109
2016
Q4 		$18K Sell
248
-115
-32% -$7.48K ﹤0.01% 3285
2016
Q3 		$22K Hold
363
– – ﹤0.01% 3270
2016
Q2 		$23K Buy
363
+234
+181% +$15.1K ﹤0.01% 3231
2016
Q1 		$8K Buy
+129
New +$7.61K ﹤0.01% 3248

Other funds holding UTMD

BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MA
Minerva Advisors Bala Cynwyd, Pennsylvania $155M AUM 35.49% 1-Year Est. Return
Hotchkis & Wiley Capital Management
Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock's UTMD Position: Q1 2026 in Review

BlackRock increased its Utah Medical Products (UTMD) stake by 1.7% in Q1 2026, buying an estimated $196K and bringing the position to 187,649 shares worth $11.6M. The position accounts for ﹤0.01% of the portfolio, ranked #3396.

BlackRock first reported a position in UTMD in Q1 2016 and has held it in 41 quarters since. The position peaked at $24.3M in Q4 2019. 119 funds tracked by Wall St. Rank hold UTMD as of Q1 2026.

  • BlackRock held 187,649 shares of Utah Medical Products worth $11.6M as of Q1 2026.
  • BlackRock bought 3,112 Utah Medical Products shares in Q1 2026, an estimated $196K.
  • Utah Medical Products made up ﹤0.01% of BlackRock's portfolio in Q1 2026, its #3396 holding.
  • BlackRock first reported a position in Utah Medical Products in Q1 2016 and has held it in 41 quarters since.
  • BlackRock's Utah Medical Products position peaked at $24.3M in Q4 2019.
  • 119 funds tracked by Wall St. Rank held Utah Medical Products as of Q1 2026.

Based on BlackRock's 13F filing for Q1 2026, filed 13 May 2026.